Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1817 - 1824 of 11454 results
Massachusetts Information Security and Privacy Act Sent to “Study”
June 2, 2022| Blog| Viewpoint
How Big Law Aims to Make Good on ‘Meritocracy’, Lessen Pay Gap
June 2, 2022| News
FTC to Twitter: Do What You Say (Or Pay $150M If You Don’t)
June 1, 2022| Blog| Viewpoint
FBI Director Wray Says FBI Blocked Planned Cyberattack on Boston Children’s Hospital
June 1, 2022| Blog| Viewpoint
Monthly TCPA Digest — May 2022
May 31, 2022| Article| Viewpoint
TCPA Regulatory Update — Commission Adopts New Rules for “Gateway Providers”
May 31, 2022| Article| Viewpoint
Potential Pitfalls of Telehealth Prescribing
May 31, 2022| Blog| Viewpoint
News & Press Releases
Venture Mega-Rounds Return to Biotech
September 26, 2024
Member Cheryl Reicin was quoted in WSJ Pro Venture Capital in an article about how venture mega rounds are becoming more frequent in the biotech industry. Specifically, Cheryl discusses the need for startups to be aware of the pressures and implications that may come from larger funding rounds.
Lenovo’s Setback in Ericsson ITC Case May Impact Other SEP Disputes
September 26, 2024
Intellectual Property Division Chair Michael Renaud was quoted by IAM in an article about the ITC case between Ericsson and Lenovo and its potential implications for FRAND negotiations. While most ITC cases involving Standard Essential Patents (SEPs) have resulted in no violation findings, this case could change that.
Mintz Ranked in 2025 Edition of Chambers Canada
September 26, 2024
Mintz announced that it has been ranked in the 2025 edition of Chambers Canada. The firm was rankedin both the Life Sciences and Cannabis Law categories. Six attorneys were also ranked in individual categories including Life Sciences, Private Equity, Investment Funds, Cannabis, and Pensions & Benefits.